DOCSLIB.ORG

Inhibition of Soluble Epoxide Hydrolase Modulates Inflammation and Autophagy in Obese Adipose Tissue and Liver: Role for Omega-3 Epoxides

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inhibition of Soluble Epoxide Hydrolase Modulates Inflammation and Autophagy in Obese Adipose Tissue and Liver: Role for Omega-3 Epoxides Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: Role for omega-3 epoxides Cristina López-Vicarioa, José Alcaraz-Quilesa, Verónica García-Alonsoa, Bibiana Riusa, Sung H. Hwangb, Esther Titosa,c, Aritz Lopategia, Bruce D. Hammockb,1, Vicente Arroyoc,d, and Joan Clàriaa,c,e,1 aDepartment of Biochemistry and Molecular Genetics, dLiver Unit, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), cCentro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas, and eDepartment of Physiological Sciences I, University of Barcelona, Barcelona 08036, Spain; and bDepartment of Entomology and Comprehensive Cancer Center, University of California, Davis, CA 95616 Contributed by Bruce D. Hammock, December 4, 2014 (sent for review July 25, 2014; reviewed by Karsten Gronert and Steve Watkins) Soluble epoxide hydrolase (sEH) is an emerging therapeutic target levels by targeting the enzyme soluble epoxide hydrolase (sEH) in a number of diseases that have inflammation as a common are currently under investigation. sEH is a cytosolic enzyme with underlying cause. sEH limits tissue levels of cytochrome P450 (CYP) epoxide hydrolase and lipid phosphatase activities that catalyzes epoxides derived from omega-6 and omega-3 polyunsaturated the rapid hydrolysis of EETs, EEQs and EDPs by adding water fatty acids (PUFA) by converting these antiinflammatory mediators to these EpFA and converting them into inactive or less active into their less active diols. Here, we explored the metabolic effects 1,2-diols (10). Accordingly, inhibition of sEH exerts beneficial of a sEH inhibitor (t-TUCB) in fat-1 mice with transgenic expression actions in controlling vascular tone, inflammation, and pain, and of an omega-3 desaturase capable of enriching tissues with endog- this strategy has shown its therapeutic potential for long-term use in hypertension, diabetes, renal disease, organ damage, and enous omega-3 PUFA. These mice exhibited increased CYP1A1, – CYP2E1, and CYP2U1 expression and abundant levels of the vascular remodeling (6, 9 12). The aim of the present study was to investigate the potential omega-3–derived epoxides 17,18-epoxyeicosatetraenoic acid metabolic benefits of sEH inhibition in obesity. Specifically, this (17,18-EEQ) and 19,20-epoxydocosapentaenoic (19,20-EDP) in insulin- study addresses the question as to whether sEH inhibition sensitive tissues, especially liver, as determined by LC-ESI-MS/MS. increases the effectiveness of omega-3–derived epoxides in obese In obese fat-1 mice, t-TUCB raised hepatic 17,18-EEQ and 19,20-EDP – adipose tissue and liver in the context of enriched omega-3 tissue levels and reinforced the omega-3 dependent reduction observed content. fat-1 mice with transgenic expression of the Caeno- t in tissue inflammation and lipid peroxidation. -TUCB also pro- rhabditis elegans omega-3 fatty acid desaturase gene represent fat-1 duced a more intense antisteatotic action in obese mice, as a useful model to address this question because these mice have revealed by magnetic resonance spectroscopy. Notably, t-TUCB abundant tissue omega-3 distribution from their embryonic stage skewed macrophage polarization toward an antiinflammatory M2 phenotype and expanded the interscapular brown adipose Significance tissue volume. Moreover, t-TUCBrestoredhepatic levels of Atg12- Atg5 and LC3-II conjugates and reduced p62 expression, indicating up-regulation of hepatic autophagy. t-TUCB consistently reduced Our study demonstrates that stabilization of cytochrome P-450 endoplasmic reticulum stress demonstrated by the attenuation of epoxides derived from omega-3 polyunsaturated fatty acids IRE-1α and eIF2α phosphorylation. These actions were recapitu- through inhibition of the inactivating enzyme soluble epoxide lated in vitro in palmitate-primed hepatocytes and adipocytes in- hydrolase (sEH) exerts beneficial actions in counteracting cubated with 19,20-EDP or 17,18-EEQ. Relatively similar but less metabolic disorders associated with obesity. In addition, our pronounced actions were observed with the omega-6 epoxide, study sheds more light on the role of sEH in cellular homeo- 14,15-EET, and nonoxidized DHA. Together, these findings identify stasis by providing evidence that omega-3 epoxides and sEH omega-3 epoxides as important regulators of inflammation and inhibition regulate autophagy and endoplasmic reticulum autophagy in insulin-sensitive tissues and postulate sEH as a drug- stress in insulin-sensitive tissues, especially the liver. Therefore, gable target in metabolic diseases. administration of a sEH inhibitor is a promising strategy to prevent obesity-related comorbidities. obesity | inflammation | autophagy | omega-3–derived epoxides | Author contributions: C.L.-V., V.A., and J.C. designed research; C.L.-V., J.A.-Q., V.G.-A., soluble epoxide hydrolase B.R., E.T., A.L., and J.C. performed research; C.L.-V., S.H.H., and B.D.H. contributed new reagents/analytic tools; C.L.-V. and J.C. analyzed data; and C.L.-V., B.D.H., and J.C. wrote ytochrome P450 (CYP) epoxygenases represent the third the paper. Cbranch of polyunsaturated fatty acid (PUFA) metabolism (1). Reviewers: K.G., University of California, Berkeley; and S.W., Lipomics Technologies Inc. CYP epoxygenases add oxygen across one of the four double bonds Conflict of interest statement: B.D.H. and S.H.H. are authors on a patent held by the University of California on the synthesis of soluble epoxide hydrolase (sEH) inhibitors. of PUFA to generate three-membered ethers known as epoxides B.D.H. founded a company, EicOsis, to move these inhibitors to the clinic to treat neuro- (1). In the case of arachidonic acid, CYP epoxygenases convert this pathic and inflammatory pain. The published and freely available sEH inhibitor was pro- omega-6 PUFA into epoxyeicosatrienoic acids (EETs), which act as vided by University of California, Davis to the Claria group in Spain along with additional autocrine or paracrine factors in the regulation of vascular tone, reagents and data. The inhibitor was a key tool to test the hypothesis that the omega-6 and 3 fatty acid epoxides were responsible for biological effects. It is conceivable that use inflammation, hyperalgesia, and organ and tissue regeneration of an sEH inhibitor could be of some benefit to EicOsis or GSK, both of which are working (2, 3). In addition to omega-6s, CYP epoxygenases also convert the to develop these materials clinically. However, numerous papers have been published omega-3 PUFA eicosapentaenoic acid (EPA) and docosahexaenoic already implicating these inhibitors in diabetes treatment, and other inhibitors of similar acid (DHA) into novel epoxyeicosatetraenoic (EEQs) and epoxy- structure and potency are commercially available from Cayman Chemical and CalBio- chem. B.D.H. is an author on University of California patents in the area, has stock in docosapentaenoic (EDPs) acids, respectively (4, 5). These omega- EicOsis, which has licensed these patents, but has no salary from EicOsis. – 3 derived epoxides also exert salutary actions and are even more 1To whom correspondence may be addressed. Email: [email protected] or bdhammock@ effective and potent than omega-6–derived EETs (4–8). ucdavis.edu. Because the predicted in vivo half-lives of fatty acid epoxides This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. (EpFA) are in the order of seconds (9), drugs that stabilize their 1073/pnas.1422590112/-/DCSupplemental. 536–541 | PNAS | January 13, 2015 | vol. 112 | no. 2 www.pnas.org/cgi/doi/10.1073/pnas.1422590112 Downloaded by guest on September 25, 2021 17,18-EEQ 19,20-EDP WT Fat-1 1.5 A B ** A Liver eWAT Liver eWAT ** Chow 600 Chow HFD Chow HFD Chow HFD Chow HFD HFD EPA DHA *** 1.0 eWAT sEH 400 * CYPs * 0.5 ** β-actin 200 Fold Change vs. Chow 0.0 17,18-EEQ 19,20-EDP Liver eWAT Liver eWAT ng/g of tissue WT Fat-1 COOH COOH 0 WT Fat-1 WT Fat-1 Chow WT Fat-1 B 2500 2200 O O 17,18-EEQ 19,20-EDP HFD * 2000 2000 2000 *** 1500 sEH ** 1800 1000 ** 1000 1000 ** * ng/g tissue 200 500 ** ** ng/g tissue 500 * Liver ** ** * * 0 0 Inactive metabolites 160 t-TUCB - + - + - + - + - + - + t-TUCB - + - + - + - + - + - + * 17,18- 19,20- 5,6- 8,9- 11,12- 14,15- 17,18- 19,20- 5,6- 8,9- 11,12- 14,15- EEQ EDP EET EET EET EET EEQ EDP EET EET EET EET ng/g of tissue 100 * 0 WT Fat-1 WT Fat-1 WT Fat-1 350 800 C 300 250 600 C D 200 400 400 5,6-EET 8,9-EET 11,12-EET 14,15-EET 150 * 100 * 300 ng/g tissue 200 AA * ng/g tissue 50 *** ** 0 0 200 eWAT t-TUCB - + - + - + - + - + - + t-TUCB - + - + - + - + - + - + CYPs 17,18- 19,20- 5,6- 8,9- 11,12- 14,15- 17,18- 19,20- 5,6- 8,9- 11,12- 14,15- DiHETE DiHDPA DHET DHET DHET DHET DiHETE DiHDPA DHET DHET DHET DHET ng/g of tissue 100 ** * Liver eWAT 0 * ** ** ** * 5,6-EET 8,9-EET 11,12-EET 14,15-EET WT Fat-1 WT Fat-1 WT Fat-1 WT Fat-1 Chow D WT Fat-1 E WT Fat-1 WT Fat-1 O O t COOH -TUCB - + - + -+ -+ COOH COOH COOH HFD 17,18-EEQ 19,20-EDP 17,18-EEQ 19,20-EDP O DiHETE DiHDPA DiHETE DiHDPA sEH O 1500 5,6-EET 8,9-EET 11,12-EET 14,15-EET *** *** 14 β-actin *** * sEH 1000 * 12 5 * *** *** *** Liver *** * * 10 4 500 *** *** 8 6 -actin 3 ** Ratio ng/g of tissue * 4 β Inactive metabolites 0.9 ** 2 0 0.6 sEH/ WT Fat-1 WT Fat-1 WT Fat-1 WT Fat-1 *** 1 active metabolites/diols 0.3 0 0.0 WT Fat-1 WT Fat-1 t Fig.
Load more

Recommended publications
  • Functional Properties and Molecular Architecture of Leukotriene A4 Hydrolase, a Pivotal Catalyst of Chemotactic Leukotriene Formation
    Review Article TheScientificWorldJOURNAL (2002) 2, 1734–1749 ISSN 1537-744X; DOI 10.1100/tsw.2002.810 Functional Properties and Molecular Architecture of Leukotriene A4 Hydrolase, a Pivotal Catalyst of Chemotactic Leukotriene Formation Jesper Z. Haeggström1,*, Pär Nordlund2, and Marjolein M.G.M. Thunnissen2 1Department of Medical Biochemistry and Biophysics, Division of Chemistry 2, Karolinska Institutet, S-171 77 Stockholm, Sweden; 2Department of Biochemistry, University of Stockholm, Arrhenius Laboratories A4, S-106 91 Stockholm, Sweden E-mail: [email protected]; [email protected]; [email protected] Received March 25, 2002; Accepted April 26, 2002; Published June 26, 2002 The leukotrienes are a family of lipid mediators involved in inflammation and allergy. Leukotriene B4 is a classical chemoattractant, which triggers adherence and aggregation of leukocytes to the endothelium at only nM concentrations. In addition, leukotriene B4 modulates immune responses, participates in the host defense against infections, and is a key mediator of PAF-induced lethal shock. Because of these powerful biological effects, leukotriene B4 is implicated in a variety of acute and chronic inflammatory diseases, e.g., nephritis, arthritis, dermatitis, and chronic obstructive pulmonary disease. The final step in the biosynthesis of leukotriene B4 is catalyzed by leukotriene A4 hydrolase, a unique bifunctional zinc metalloenzyme with an anion-dependent aminopeptidase activity. Here we describe the most recent developments regarding our understanding
    [Show full text]
  • Role of Epoxide Hydrolases in Lipid Metabolism
    Biochimie 95 (2013) 91e95 Contents lists available at SciVerse ScienceDirect Biochimie journal homepage: www.elsevier.com/locate/biochi Mini-review Role of epoxide hydrolases in lipid metabolism Christophe Morisseau* Department of Entomology and U.C.D. Comprehensive Cancer Center, One Shields Avenue, University of California, Davis, CA 95616, USA article info abstract Article history: Epoxide hydrolases (EH), enzymes present in all living organisms, transform epoxide-containing lipids to Received 29 March 2012 1,2-diols by the addition of a molecule of water. Many of these oxygenated lipid substrates have potent Accepted 8 June 2012 biological activities: host defense, control of development, regulation of blood pressure, inflammation, Available online 18 June 2012 and pain. In general, the bioactivity of these natural epoxides is significantly reduced upon metabolism to diols. Thus, through the regulation of the titer of lipid epoxides, EHs have important and diverse bio- Keywords: logical roles with profound effects on the physiological state of the host organism. This review will Epoxide hydrolase discuss the biological activity of key lipid epoxides in mammals. In addition, the use of EH specific Epoxy-fatty acids Cholesterol epoxide inhibitors will be highlighted as possible therapeutic disease interventions. Ó Juvenile hormone 2012 Elsevier Masson SAS. All rights reserved. 1. Introduction hydrolyzed by a water molecule [8]. Based on this mechanism, transition-state inhibitors of EHs have been designed (Fig. 1B). Epoxides are three atom cyclic ethers formed by the oxidation of These ureas and amides are tight-binding competitive inhibitors olefins. Because of their highly polarized oxygen-carbon bonds and with low nanomolar dissociation constants (KI) [9] [10].
    [Show full text]
  • Quantum Chemical Studies of Epoxide- Transforming Enzymes
    Quantum Chemical Studies of Epoxide- Transforming Enzymes Kathrin H. Hopmann Department of Theoretical Chemistry Royal Institute of Technology Stockholm, Sweden, 2007 ii © Kathrin H. Hopmann, 2007 ISBN 978-91-7178-640-1 ISSN 1654-2312 TRITA-BIO-Report 2007:3 Printed by Universitetsservice US-AB, Stockholm, Sweden. iii Abstract Density functional theory is employed to study the reaction mechanisms of different epoxide-transforming enzymes. Calculations are based on quantum chemical active site models, which are build from X-ray crystal structures. The models are used to study conversion of various epoxides into their corresponding diols or substituted alcohols. Epoxide-transforming enzymes from three different families are studied. The human soluble epoxide hydrolase (sEH) belongs to the α/β-hydrolase fold family. sEH employs a covalent mechanism to hydrolyze various epoxides into vicinal diols. The Rhodococcus erythrobacter limonene epoxide hydrolase (LEH) constitutes a novel epoxide hydrolase, which is considered the founding member of a new family of enzymes. LEH mediates transformation of limone-1,2-epoxide into the corresponding vicinal diol by employing a general acid/general base-mediated mechanism. The Agrobacterium radiobacter AD1 haloalcohol dehalogenase HheC is related to the short-chain dehydrogenase/reductases. HheC is able to convert epoxides using various nucleophiles such as azide, cyanide, and nitrite. Reaction mechanisms of these three enzymes are analyzed in depth and the role of different active site residues is studied through in silico mutations. Steric and electronic factors influencing the regioselectivity of epoxide opening are identified. The computed energetics help to explain preferred reaction pathways and experimentally observed regioselectivities. Our results confirm the usefulness of the employed computational methodology for investigating enzymatic reactions.
    [Show full text]
  • Download (2MB)
    Enzyme and Microbial Technology 139 (2020) 109592 Contents lists available at ScienceDirect Enzyme and Microbial Technology journal homepage: www.elsevier.com/locate/enzmictec Identification and catalytic properties of new epoxide hydrolases fromthe T genomic data of soil bacteria Gorjan Stojanovskia, Dragana Dobrijevica, Helen C. Hailesb, John M. Warda,* a Department of Biochemical Engineering, University College London, Bernard Katz, London WC1E 6BT, UK b Department of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, UK ARTICLE INFO ABSTRACT Keywords: Epoxide hydrolases (EHs) catalyse the conversion of epoxides into vicinal diols. These enzymes have extensive Epoxide hydrolase value in biocatalysis as they can generate enantiopure epoxides and diols which are important and versatile Limonene epoxide hydrolase synthetic intermediates for the fine chemical and pharmaceutical industries. Despite these benefits, theyhave Genome mining seen limited use in the bioindustry and novel EHs continue to be reported in the literature. Biotransformation We identified twenty-nine putative EHs within the genomes of soil bacteria. Eight of these EHs wereexplored in terms of their activity. Two limonene epoxide hydrolases (LEHs) and one ⍺/β EH were active on a model compound styrene oxide and its ring-substituted derivatives, with low to good percentage conversions of 18–86%. Further exploration of the substrate scope with enantiopure (R)-styrene oxide and (S)-styrene oxide, showed different epoxide ring opening regioselectivities. Two enzymes, expressed from plasmids pQR1984and pQR1990 de-symmetrised the meso-epoxide cyclohexene oxide, forming the (R,R)-diol with high enantioselec- tivity. Two LEHs, from plasmids pQR1980 and pQR1982 catalysed the hydrolysis of (+) and (−) limonene oxide, with diastereomeric preference for the (1S,2S,4R)- and (1R,2R,4S)-diol products, respectively.
    [Show full text]
  • NST110: Advanced Toxicology Lecture 4: Phase I Metabolism
    Absorption, Distribution, Metabolism and Excretion (ADME): NST110: Advanced Toxicology Lecture 4: Phase I Metabolism NST110, Toxicology Department of Nutritional Sciences and Toxicology University of California, Berkeley Biotransformation The elimination of xenobiotics often depends on their conversion to water-soluble chemicals through biotransformation, catalyzed by multiple enzymes primarily in the liver with contributions from other tissues. Biotransformation changes the properties of a xenobiotic usually from a lipophilic form (that favors absorption) to a hydrophilic form (favoring excretion in the urine or bile). The main evolutionary goal of biotransformation is to increase the rate of excretion of xenobiotics or drugs. Biotransformation can detoxify or bioactivate xenobiotics to more toxic forms that can cause tumorigenicity or other toxicity. Phase I and Phase II Biotransformation Reactions catalyzed by xenobiotic biotransforming enzymes are generally divided into two groups: Phase I and phase II. 1. Phase I reactions involve hydrolysis, reduction and oxidation, exposing or introducing a functional group (-OH, -NH2, -SH or –COOH) to increase reactivity and slightly increase hydrophilicity. O R1 - O S O sulfation O R2 OH Phase II Phase I R1 R2 R1 R2 - hydroxylation COO R1 O O glucuronidation OH R2 HO excretion OH O COO- HN H -NH2 R R1 R1 S N 1 Phase I Phase II COO O O oxidation glutathione R2 OH R2 R2 conjugation 2. Phase II reactions include glucuronidation, sulfation, acetylation, methylation, conjugation with glutathione, and conjugation with amino acids (glycine, taurine and glutamic acid) that strongly increase hydrophilicity. Phase I and II Biotransformation • With the exception of lipid storage sites and the MDR transporter system, organisms have little anatomical defense against lipid soluble toxins.
    [Show full text]
  • Regioselectivity Engineering of Epoxide Hydrolase: Near-Perfect Enantioconvergence Through a Single Site Mutation
    Letter Cite This: ACS Catal. 2018, 8, 8314−8317 pubs.acs.org/acscatalysis Regioselectivity Engineering of Epoxide Hydrolase: Near-Perfect Enantioconvergence through a Single Site Mutation † # † ‡ # † † § † Fu-Long Li, , Xu-Dong Kong, , , Qi Chen, Yu-Cong Zheng, Qin Xu, Fei-Fei Chen, † ‡ ‡ † † Li-Qiang Fan, Guo-Qiang Lin, Jiahai Zhou,*, Hui-Lei Yu,*, and Jian-He Xu*, † State Key Laboratory of Bioreactor Engineering, Shanghai Collaborative Innovation Center for Biomanufacturing Technology, East China University of Science and Technology, Shanghai 200237, China ‡ Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China § State Key Laboratory of Microbial Metabolism, and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China *S Supporting Information ABSTRACT: An epoxide hydrolase from Vigna radiata (VrEH2) affords partial enantioconvergence (84% ee)intheenzymatic hydrolysis of racemic p-nitrostyrene oxide (pNSO), mainly due to ffi α β insu cient regioselectivity for the (S)-enantiomer (rS = S/ S = 7.3). To improve the (S)-pNSO regioselectivity, a small but smart library of VrEH2 mutants was constructed by substituting each of four key residues lining the substrate binding site with a simplified amino acid alphabet of Val, Asn, Phe, and Trp. Among the mutants, M263N attacked almost exclusively at Cα in the (S)-epoxide ring with satisfactory regioselectivity (rS = 99.0), without compromising the original high regioselectivity for the (R)-epoxide (rR = 99.0), resulting in near-perfect enantioconvergence (>99% analytical yield, 98% ee). Structural and conformational analysis showed that the introduced Asn263 formed additional hydrogen bonds with the nitro group in substrate, causing a shift in the substrate binding pose.
    [Show full text]
  • Capturing LTA4 Hydrolase in Action: Insights to the Chemistry and Dynamics of Chemotactic LTB4 Synthesis Alena Stsiapanavaa, Bengt Samuelssona,1, and Jesper Z
    Capturing LTA4 hydrolase in action: Insights to the chemistry and dynamics of chemotactic LTB4 synthesis Alena Stsiapanavaa, Bengt Samuelssona,1, and Jesper Z. Haeggströma,1 aDivision of Physiological Chemistry II, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden Contributed by Bengt Samuelsson, July 29, 2017 (sent for review June 19, 2017; reviewed by Marcia E. Newcomer and Takao Shimizu) Human leukotriene (LT) A4 hydrolase/aminopeptidase (LTA4H) is a present report, we describe successful trapping and structure bifunctional enzyme that converts the highly unstable epoxide determination of LTA4H-LTA4 complexes providing insights to intermediate LTA4 into LTB4, a potent leukocyte activating agent, the EH mechanism. Moreover, we show that LTA4H undergoes while the aminopeptidase activity cleaves and inactivates the che- domain movements, with structural alterations indicating gated motactic tripeptide Pro-Gly-Pro. Here, we describe high-resolution substrate entrance into the active site followed by induced fit to crystal structures of LTA4H complexed with LTA4, providing the achieve optimal alignment and catalysis. structural underpinnings of the enzyme’s unique epoxide hydro- + lase (EH) activity, involving Zn2 , Y383, E271, D375, and two cata- Results and Discussion lytic waters. The structures reveal that a single catalytic water is In this study, we describe six different structures of LTA4H from involved in both catalytic activities of LTA4H, alternating between five distinct crystal forms. These visualize two conformational epoxide ring opening and peptide bond hydrolysis, assisted by states of the enzyme (Tables S1 and S2). The mutants we in- E271 and E296, respectively. Moreover, we have found two con- vestigated include variants E271A (12), D375N (13), and R563A formations of LTA4H, uncovering significant domain movements.
    [Show full text]
  • Ω-3 Polyunsaturated Fatty Acids on Colonic Inflammation and Colon Cancer: Roles of Lipid- Metabolizing Enzymes Involved
    Review ω-3 Polyunsaturated Fatty Acids on Colonic Inflammation and Colon Cancer: Roles of Lipid- Metabolizing Enzymes Involved Maolin Tu 1,2, Weicang Wang 3, Guodong Zhang 1,4 and Bruce D. Hammock 3,* 1 Department of Food Science, University of Massachusetts, Amherst, MA 01002, USA; [email protected] (M.T.); [email protected] (G.Z.) 2 Department of Food Science and Technology, National Engineering Research Center of Seafood, Collaborative Innovation Center of Seafood Deep Processing, Dalian Polytechnic University, Dalian 116034, China 3 Department of Entomology and Comprehensive Cancer Center, University of California, Davis, CA 95616, USA; [email protected] 4 Molecular and Cellular Biology Graduate Program, University of Massachusetts, Amherst, MA 01002, USA * Correspondence: [email protected]; Tel.: +1-530-752-7519 Received: 23 September 2020; Accepted: 24 October 2020; Published: 28 October 2020 Abstract: Substantial human and animal studies support the beneficial effects of ω-3 polyunsaturated fatty acids (PUFAs) on colonic inflammation and colorectal cancer (CRC). However, there are inconsistent results, which have shown that ω-3 PUFAs have no effect or even detrimental effects, making it difficult to effectively implement ω-3 PUFAs for disease prevention. A better understanding of the molecular mechanisms for the anti-inflammatory and anticancer effects of ω-3 PUFAs will help to clarify their potential health-promoting effects, provide a scientific base for cautions for their use, and establish dietary recommendations. In this review, we summarize recent studies of ω-3 PUFAs on colonic inflammation and CRC and discuss the potential roles of ω-3 PUFA-metabolizing enzymes, notably the cytochrome P450 monooxygenases, in mediating the actions of ω-3 PUFAs.
    [Show full text]
  • The Rhodococcus Erythropolis DCL14 Limonene-1,2-Epoxide Hydrolase Gene Encodes an Enzyme Belonging to a Novel Class of Epoxide Hydrolases
    View metadata,FEBS 21078 citation and similar papers at core.ac.uk FEBS Letters 438 (1998)brought to293^296 you by CORE provided by Elsevier - Publisher Connector The Rhodococcus erythropolis DCL14 limonene-1,2-epoxide hydrolase gene encodes an enzyme belonging to a novel class of epoxide hydrolases Fabien Barbirato, Jan C. Verdoes, Jan A.M. de Bont, Marieët J. van der Werf* Division of Industrial Microbiology, Department of Food Technology and Nutritional Sciences, Wageningen University and Research Centre, P.O. Box 8129, 6700 EV Wageningen, The Netherlands Received 8 September 1998; received in revised form 7 October 1998 the three-dimensional structure has been solved [16]. Epoxide Abstract Recently, we reported the purification of the novel enzyme limonene-1,2-epoxide hydrolase involved in limonene hydrolases do not contain a prosthetic group. The K,L-hydro- degradation by Rhodococcus erythropolis DCL14. The N-term- lase fold epoxide hydrolases have a two-domain organization. inal amino acid sequence of the purified enzyme was used to Domain I consists of an K,L-sheet that forms a catalytic pock- design two degenerate primers at the beginning and the end of the et and domain II, which splits domain I, sits like a lid over the 50 amino acids long stretch. Subsequently, the complete catalytic cleft [14]. The catalytic activity of K,L-hydrolase fold limonene-1,2-epoxide hydrolase gene (limA) was isolated from epoxide hydrolases depends on a catalytic triad consisting of a genomic library of R. erythropolis DCL14 using a combination Asp, His, and Asp(Glu) residues [15,17].
    [Show full text]
  • Metabolism Pathways of Arachidonic Acids: Mechanisms and Potential Therapeutic Targets
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets Bei Wang1,2,3, Lujin Wu1,2, Jing Chen1,2, Lingli Dong3, Chen Chen 1,2, Zheng Wen1,2, Jiong Hu4, Ingrid Fleming4 and Dao Wen Wang1,2 The arachidonic acid (AA) pathway plays a key role in cardiovascular biology, carcinogenesis, and many inflammatory diseases, such as asthma, arthritis, etc. Esterified AA on the inner surface of the cell membrane is hydrolyzed to its free form by phospholipase A2 (PLA2), which is in turn further metabolized by cyclooxygenases (COXs) and lipoxygenases (LOXs) and cytochrome P450 (CYP) enzymes to a spectrum of bioactive mediators that includes prostanoids, leukotrienes (LTs), epoxyeicosatrienoic acids (EETs), dihydroxyeicosatetraenoic acid (diHETEs), eicosatetraenoic acids (ETEs), and lipoxins (LXs). Many of the latter mediators are considered to be novel preventive and therapeutic targets for cardiovascular diseases (CVD), cancers, and inflammatory diseases. This review sets out to summarize the physiological and pathophysiological importance of the AA metabolizing pathways and outline the molecular mechanisms underlying the actions of AA related to its three main metabolic pathways in CVD and cancer progression will provide valuable insight for developing new therapeutic drugs for CVD and anti-cancer agents such as inhibitors of EETs or 2J2. Thus, we herein present a synopsis of AA metabolism in human health, cardiovascular and cancer biology, and the signaling pathways involved in these processes. To explore the role of the AA metabolism and potential therapies, we also introduce the current newly clinical studies targeting AA metabolisms in the different disease conditions.
    [Show full text]
  • Mobilization of Iron Stored in Bacterioferritin Is Required for Metabolic Homeostasis in Pseudomonas Aeruginosa
    SUPPORTING INFORMATION Mobilization of Iron Stored in Bacterioferritin is Required for Metabolic Homeostasis in Pseudomonas aeruginosa Achala N. D. Punchi Hewage 1, Leo Fontenot 2, Jessie Guidry 3, Thomas Weldeghiorghis 2, Anil K. Mehta 4, Fabrizio Donnarumma 2, and Mario Rivera 2,* 1 Department of Chemistry, University of Kansas, 2030 Becker Dr., Lawrence, KS, 66047, USA; [email protected] 2 Department of Chemistry, Louisiana State University, 232 Choppin Hall, Baton Rouge, LA, 70803, USA; [email protected] (L.F); [email protected] (T.W); [email protected] (F.D) 3 Department of Biochemistry and Molecular Biology, Louisiana State University Health Science Center, 1901 Perdido Street, New Orleans, LA, 70112, USA; [email protected] 4 National High Magnetic Field Laboratory, University of Florida, 1149 Newell Drive, Gainesville, FL, 32610, USA; [email protected]. *Corresponding author. E-mail: [email protected] ORCID: 0000-0002-5692-5497 Figure S1. Growth curves and levels of pyoverdine secreted by wt and Δbfd P. aeruginosa cells. (A) P. aeruginosa cells (wt and Δbfd) were cultured in PI media supplemented with 10 µM Fe at 37 °C and shaking at 220 rpm. For the purpose of all the analyses reported in this work, the cells were harvested by centrifugation 30 h post inoculation. (B) Pyoverdine secreted by the cells was measured in the cell-free supernatants by acquiring fluorescence emission spectra (430-550 nm) with excitation at 400 nm (10 nm slit width) and emission at 460 nm (10 nm slit width). Fluorescence intensity normalized to viable cell count (CFU/mL) shows that the Δbfd cells secrete approximately sixfold more pyoverdine than the wt cells.
    [Show full text]
  • Inhibition of Microsomal Epoxide Hydrolases by Ureas, Amides, and Amines
    Chem. Res. Toxicol. 2001, 14, 409-415 409 Inhibition of Microsomal Epoxide Hydrolases by Ureas, Amides, and Amines Christophe Morisseau, John W. Newman, Deanna L. Dowdy, Marvin H. Goodrow, and Bruce D. Hammock* Department of Entomology and University of California Cancer Center, University of California, Davis, California 95616 Received August 11, 2000 The microsomal epoxide hydrolase (mEH) plays a significant role in the metabolism of xenobiotics such as polyaromatic toxicants. Additionally, polymorphism studies have underlined a potential role of this enzyme in relation to several diseases, such as emphysema, spontaneous abortion, and several forms of cancer. To provide new tools for studying the function of mEH, inhibition of this enzyme was investigated. Inhibition of recombinant rat and human mEH was achieved using primary ureas, amides, and amines. Several of these compounds are more potent than previously published inhibitors. Elaidamide, the most potent inhibitor that is obtained, has a Ki of 70 nM for recombinant rat mEH. This compound interacts with the enzyme forming a noncovalent complex, and blocks substrate turnover through an apparent mix of competitive and noncompetitive inhibition kinetics. Furthermore, in insect cell cultures expressing rat mEH, elaidamide enhances the toxicity effects of epoxide-containing xenobiotics. These inhibitors could be valuable tools for investigating the physiological and toxicological roles of mEH. Introduction Over the past decade, mEH was also described as mediating the transport of bile acid into hepatocytes (14, Epoxides are highly strained three-membered cyclic 15). The mechanism by which mEH participates in bile ethers that are often electrophilically reactive mutagens, absorption is not known. Obtaining potent mEH inhibi- carcinogens, or cytotoxins (1).
    [Show full text]